Article
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Journal of medical economics - 1 Aug 2016
Saab Sammy, Parisé Hélène, Virabhak Suchin, Wang Alice, Marx Steven E, Sanchez Gonzalez Yuri, Misurski Derek, Johnson Scott
Abstract excerpt
OBJECTIVE: This study compared the cost-effectiveness of direct-acting antiviral therapies currently recommended for treating genotypes (GT) 1 and 4 chronic hepatitis C (CHC) patients in the US. METHODS: A cost-effectiveness analysis of treatments for CHC from a US payer's perspective over a lifelong time horizon was performed. A Markov model based on the natural history of CHC was used for a population that...
Topics
- 2-Naphthylamine
- Adult
- Aged
- Aged, 80 and over
- Anilides
- Antiviral Agents
- Benzimidazoles
- Carbamates
- Carcinoma, Hepatocellular
- Cost-Benefit Analysis
- Cyclopropanes
- Drug Therapy, Combination
- Female